Kornimate/medical-research-clean huggingface dataset:
tongue depressor-related tongue swelling

Conditions: Children, Only; Adenoidal Hypertrophy; Adenoid Disease - Chronic; Complication; Side Effect

Summary: this study aimed to detect tongue swelling induced by the pressure exerted by tongue depressor; swelling detection was made through tongue surface area measurement using ultrasonography (usg) in pediatric patients who underwent adenoidectomy surgeries.

the tongue is an ideal organ for ultrasonography (usg) evaluation. this study aimed to detect the occurrence of tongue swelling through usg examination and to educate clinicians about the association between subacute tongue swelling and tongue depressor in pediatric patients.

Eligibility criteria:
inclusion criteria: * patients aged 16 years or younger * undergo adenoidectomy surgery * patients informed consent obtained from the parents inclusion criteria for control group: * patients aged 16 years or younger * patients who did not need adenoidectomy surgery and any head and neck procedures * patients who underwent endotracheal intubation under general anesthesia except adenoidectomy and head and neck surgery. exclusion criteria: * patients aged older than 16 years * patients with a history of syndromal craniofacial abnormalities * patients with systemic disorders and other otolaryngologic problems

Keywords: children tongue disease ultrasonography enlarge tongue adenoid
a collaborative trial in injectors of individualized treatment for genotype 2/3

Conditions: Hepatitis C, Chronic

Summary: this sudy will determine whether shortening treatment for hepatitis c is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to treatment early on.

the study will evaluate the feasibility, safety and effectiveness of shortened treatment for hepatitis c genotypes 2/3 in current injection drug users or receiving opiate substitution therapy. treatment will be with pegylated interferon alfa 2b (directly observed) and ribavirin for 12 weeks in those that have non-quantifiable (\<15 iu/ml detected and \<15 iu/ml undetected) hcv rna or undetectable hcv rna on qualitative assay at week 4 and 24 weeks in those that have quantifiable (≥15 iu/ml) hcv rna or detectable hcv rna on qualitative assay at week 4.

Eligibility criteria:
inclusion criteria: * 18 years of age * chronic hcv infection * hcv genotype 2/3 infection * active injection drug use (within 24 weeks prior to consent) or currently receiving opiate substitution therapy * compensated liver disease * negative pregnancy test (within 24 hours of first dose of study medication) * effective contraception for the duration of the study * written informed consent exclusion criteria: * previous interferon or ribavirin therapy * investigation drug use in the 6 weeks prior to first dose of study medication * infection with hcv genotypes other than 2/3 * hiv infection * hbv infection * ongoing severe psychiatric disease * frequent drug use that is judged by the treating physician to compromise treatment safety * standard clinical and medical exclusions for treatment with pegylated interferon alfa 2b and ribavirin

Keywords: hepatitis c treatment injection drug users or receiving opiate substitution therapy
soy isoflavones and breast cancer risk reduction

Conditions: Breast Cancer

Summary: soy consumption has been associated with reduced risk for developing breast cancer. soy contains isoflavones which are weak estrogens. the roles of soy isoflavones in reducing breast cancer risk are currently unclear. breast density has been considered as a breast cancer risk marker. we hypothesize that because isoflavones have estrogen-like activities, breast density and possibly bone density will be lower in women on soy-isoflavones.

this is a randomized, double-blind study, with two arms and 100 women in each arm. premenopausal women will be recruited and randomly allocated to take one of the two different dietary supplements in pills daily for 2 years. the two supplements are soy isoflavones (treatment) and placebo (carbohydrates). both treatment and placebo pills will contain multi-vitamins and minerals. multiple blood, urine, and breast fluid samples will be obtained before and during the dietary supplement periods and analyzed for biomarkers of breast cancer risk. at baseline and after the intervention period, breast density and bone density will be assessed by radiologic techniques. the efficacy of the dietary intervention will be determined by comparing mean changes of serum markers for breast cancer risk,dense breast tissue, and bone mineral density over the two year dietary intervention period in the two supplement groups with adjustment for baseline values and individual patient characteristics of interest. we predict that 2 years of soy isoflavone supplement will reduce breast density, which may be explained by individual changes in serum markers of breast cancer risk.

Eligibility criteria:
inclusion criteria: * healthy premenopausal women * 30 to 42 years old * normal mammograms * regular menstrual cycles exclusion criteria: * abnormal mammograms * first degree relatives with breast cancer * pregnant or lactating * peri- or post-menopause * breast augmentation, reduction or lifting * on oral contraceptive medications or exogenous hormones * medically prescribed diets * allergic reaction to soy products

Keywords: soy isoflavones phytoestrogens prevention mammographic density bone density
study of xl999 in patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: this clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of xl999 when given weekly to patients with relapsed or refractory multiple myeloma. xl999 is a small molecule inhibitor of cellular factors including vegfr, pdgfr, and fgfr that may be involved in multiple myeloma.


Eligibility criteria:
inclusion criteria: * males and females with a diagnosis of mm based on bone marrow aspirate and biopsy with ≥10% plasma cells (or biopsy of a tissue with monoclonal plasma cells), m protein level in the serum or urine, and evidence of end organ or tissue impairment (hypercalcemia, renal insufficiency, anemia, or lytic bone lesions), as defined by the international myeloma working group criteria (2003), at initial diagnosis (before initiation of chemotherapy) * measurable disease defined as serum and/or urine m component by electrophoresis * refractory to or relapsed after 2 prior treatment regimens (chemotherapy, biologic or hematopoietic stem cell transplantation) * concurrent therapy with a bisphosphonate is acceptable * ecog performance status of 0 or 1 * life expectancy ≥3 months * adequate liver function * no other malignancies within 5 years * signed informed consent exclusion criteria: * nonsecretory myeloma, monoclonal gammopathy of uncertain significance (mgus), or smoldering myeloma * anticancer therapy including chemotherapeutic, biologic, or investigational agents, including dexamethasone, within 30 days of xl999 treatment * hematopoietic stem cell transplantation within the previous 6 weeks * radiation to ≥33% of bone marrow within 30 days of xl999 treatment * subject has not recovered to grade ≤1 or to within 10% of baseline from adverse events due to investigational or chemotherapeutic drugs that were administered \>30 prior to study enrollment * uncontrolled and/or intercurrent illness * pregnant or breastfeeding females * known hiv
pre-deliric prediction model plus smart care to reduce the incidence of delirium in icu patients

Conditions: Intensive Care Unit Delirium

Summary: delirium is a severe acute brain dysfunction characterised by sudden confusion, inattention and fluctuating level of consciousness, which mainly affects intubated intensive care patients. it increases the risk of self-extubation, prolongs icu stay and increases mortality. the incidence of delirium in icus varies, with approximately 33.3% of patients affected, and rates of new-onset and pre-existing delirium range from 4% to 89%. accurate diagnosis is challenging, with 60-80% of patients remaining undiagnosed. early detection is critical for intervention and improved outcomes. to address these issues, the prediction of delirium (pre-deliric) model incorporates 10 risk factors and predicts delirium within 24 hours of icu admission, allowing risk stratification into low to very high risk categories. it recalibrates predictive values with a sensitivity of 91.3% and specificity of 64.4% using a cut-off score of 27%. however, its integration into delirium management is underexplored. delirium risk stratification supports efficient resource allocation, cost control, workload reduction and ethical care, while promptly identifying high-risk patients. in this study, investigators evaluate the integration of the pre-deliric model into a comprehensive delirium management approach called pre-deliric-guided smart/smart care. smart care includes improving familiarity, assessing pain and anxiety, reducing equipment discomfort and cognitive stimulation. patients with pre-deliric scores \>30% receive smart care and multidisciplinary involvement, based on the american delirium society.


Eligibility criteria:
inclusion criteria: 1. sicu patients are over 18 years old. 2. received surgery intervention exclusion criteria: 1. clinical diagnosis of mental disorders 2. underwent neurosurgical procedures, 3. discharged from the icu within 24 hours of admission 4. transitioned to active life support withdrawal or "comfort care only" within 24 hours of icu admission
efficacy of the care rule associated with the heart score in patients with emergency chest pain

Conditions: Chest Pain

Summary: acute coronary syndrome (acs) is a major public health problem and its diagnosis remains a challenge for the emergency physician. the european society of cardiology recommends a troponin dosage and renew it if necessary during any suspicion of acs. however, the criteria leading to initiate a diagnostic procedure during chest pain are imprecise. the fear is, on the one hand, to miss a potentially vital diagnosis and, on the other hand, to expose a large number of patients to unnecessary examinations. the care rule (also known as hear score) seems to streamline this first step. it assigns a value of 0 to 2 using 4 items: characteristic of pain, age, risk factors and electrocardiogram (ecg). the search for an acs is not justified if the sum of the points is \ 1 (positive rule). the aim of the study is to demonstrate the safety and interest of the care rule associated with the heart score to streamline acs's diagnostic approach to thoracic pain in emergencies departments.

data collected in this study are not anticipated to be published in a data repository. however, data will be shared per requested need to researchers, upon presentation of a structured protocol, when approved by the competent ethic committee and approved by the steering committee.

Eligibility criteria:
inclusion criteria: * admission to an emergency department participating in the study * non-traumatic chest pain * age greater than or equal to 18 years * patient's consent (oral for france, written for belgium) exclusion criteria: * 30 days follow-up not possible * st-segment elevation myocardial infarction (stemi) on admittance ecg * chest pain formally reported to a diagnosis other than an acs before inclusion (e.g., pneumothorax, pleurisy, etc.) * troponin assay performed prior to inclusion (less than 24 hours old) * patient referred by another care structure (excluding primary medicine) * patient already included in study still in follow-up period * pregnant, breastfeeding or parturient patient, * patient deprived of liberty by judicial or administrative decision, * patient undergoing psychiatric care under duress, * patient subject to a legal protection measure, * patient unable to give free and informed consent.
examination of the acute effect of mollii suit in children with cerebral palsy

Conditions: Mollii Suit; Cerebral Palsy

Summary: the aim of our study is to examine the acute effect of mollii suit application on balance and muscle tone problems in children with spastic cerebral palsy.

cerebral palsy (cp) is the most common developmental disorder in childhood. individuals' independence in daily living activities and participation in education, games, social and community activities are restricted. technology applications in the field of rehabilitation are gaining momentum. exopulse mollii suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities. therefore, the aim of our study is to examine the acute effect of mollii suit application on balance and muscle tone problems in children with spastic cerebral palsy.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * having a diagnosis of spastic cp * 1 or 2 on the gross motor classification system (gmfcs) * between the ages of 4-18. exclusion criteria: * having gmfcs 3,4,5 * botulinum toxin a performed before 3 months or surgical intervention before 6 months * having an invasive medical pump (baclofen, insulin, etc.)

Keywords: cerebral palsy mollii suit muscle tone balance
comorbidities and indirect health state utility in hip and knee osteoarthritis

Conditions: Osteoarthritis

Summary: national cohort study aimed to investigate the impact of comorbidities (number and type of comorbidities) on health utility state change in lower lim osteoarthritis (hip and knee oa).

the concept of health utility state was developed by economists to explain individual choices and preferences for health states. it is expressed as the "desirability or preference that individuals exhibit for the condition". this health utility state can be measured indirectly using health-relation quality of life questionnaires. chronic diseases such as oa are known to be associated with impairment of quality of life. given that oa prevalence increases with age, oa is often associated with other diseases (comorbidities). a cross-sectional study showed that comorbidities are associated with lower health utility state in oa. investigation of longitudinal impact of comorbidities on health utility state change is need. main objective: determine the impact of comorbidities on change in health utility state among patients with lower limb oa. secondary objective: determine the minimal clinically important difference in health utility state among patients with lower limb oa. the comutar study uses longitudinal data from the knee and hip osteoarthritis longitudinal assessment (khoala) cohort study. health utility state is measured indirectly using medical outcome study short form-36 quality of life questionnaire comorbidities are assessed using the functional comorbidity index

Eligibility criteria:
inclusion criteria: * age: 40-75 years * uni or bilateral lower limb osteoarthritis (oa) according to the american college of rheumatology (acr) and european league against rheumatism (eular) criteria exclusion criteria: * hip or knee prothesis * antecedent of osteotomy * severe comorbidity * adult under legal protection
emulsion droplet physical state on postprandial lipemia and satiety

Conditions: Postprandial Lipemia; Satiety

Summary: the purpose of this study is to compare the changes in blood lipids and feelings of satiety after consumption of oil-in-water emulsions in which the droplets are in either the liquid or solid (i.e. crystalline) states.

a double blinded randomized cross-over acute meal study will be carried out in which 15 healthy male participants will attend two study visits, separated by at least one week. on each study visit, fasted participants will consume either the solid or the liquid emulsion, in a randomized order. both emulsions tested will have the exact same composition only differing in the physical state of the lipid emulsions, in order to isolate the impact of physical state, specifically, on metabolic response. postprandial lipemia and satiety will be measured for 6 hours after consumption of the test beverage. the study meals will include crushed acetominophen, the appearance of which will be measured in plasma as a measure of liquid content gastric emptying. participants will be asked to maintain their usual lifestyle habits throughout the study, with some changes in the 48 hour period leading up to each of the two visits.

Eligibility criteria:
inclusion criteria: * bmi of 18 - 26 kg/m2 * generally healthy * non-smoking * non to moderate alcohol drinkers * fasting plasma cholesterol level \<5.2 mmol/l * plasma triacylglycerol level \<1.7 mmol/l * plasma glucose level \<5.6 mmol/l exclusion criteria: * history of major medical conditions * taking prescription medications/ over the counter medications * taking natural health products/ dietary supplements (other than a multivitamin) * oral antibiotic use in the previous 3 months * planning to take oral antibiotics in the next 3 months * food allergy/anaphylactic/life-threatening allergy * smokers/ regular users of recreational drugs * elite/ training athletes * significant weight loss/ gain during the past 3 months * previous reaction/ sensitivity to acetaminophen * inability to avoid taking acetaminophen for 48 hours * sensitivity to the artificial sweetener sugar twin® sucralose and artificial vanilla extract * not willing to consume sugar twin® sucralose or artificial vanilla.
high dose oral 4-aminosalicylic acid (paser®) to control acute flares of mild to moderate crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this 4 week study is to determine whether paser®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 4 grams three times daily for 2 weeks followed by 4 grams twice daily for 2 weeks, will resolve an acute flare of ileocecal crohn's disease.


Eligibility criteria:
inclusion criteria: * age 18-65 * crohn's disease involving predominantly the ileum and/or cecum. the diagnosis must have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3 modalities) with at least one confirmatory test having been performed no more than 36 months before entry. the diagnosis must have been confirmed by at least one gastroenterologist. * harvey bradshaw index of at least 7 * the onset of the acute flare should have been abrupt, declaring itself over 72 hours, and should have started no more than 4 weeks before study entry. symptoms relating to the flare should not have diminished or started to improve prior to entry. * written informed consent exclusion criteria: * concomitant corticosteroids, including budesonide * corticosteroids within the previous 2 months * cyclosporine, mycophenolate mofetil or experimental drugs during the last three months * maintenance infliximab, or infliximab or other biologics in the preceding 3 months * change in dose during previous 4 weeks in 5-aminosalicylate, probiotic and/or antibiotic, or in chronic azathioprine, 6-mercaptopurine, or methotrexate * if currently using azathioprine, 6-mercaptopurine or methotrexate, these must have been used steadily for at least 4 months * current experimental drugs or experimental drugs within the last 3 months * if the severity of the flare has started to decrease spontaneously * coexisting diagnosis of primary sclerosing cholangitis, * infectious diarrhea, * signs of intestinal obstruction or perforation or abscess, * new fistulization as part of the acute flare or increased activity in chronic fistula(e) as part of the acute flare, * increased activity of pre-existing anal or rectal crohn's disease as part of the flare * allergy or sensitivity to salicylates * pregnancy or breast-feeding * failure of a woman of child-bearing age to agree to use adequate contraception for the 4 week period of the trial, if sexually active * severe renal or hepatic disease

Keywords: crohn's disease acute flare mild to moderate crohn's disease ileocecal distribution
effect of lumbar stabilization exercises and circular dances in chronic non specific low back pain

Conditions: Low Back Pain

Summary: supervised exercises are the first line therapy for patients with chronic low back pain. the lumbar segmental stabilization (lse) is a specific training for the muscles of the lumbar spine, which aims to improve neuromuscular control, strength and endurance of the muscles that promotes stability to the spine. the circular dance (cd) belongs to the group of complementary and integrative practices entered in public health care in brazil, and has been used to improve several aspects related to physical and mental states such as flexibility, posture, strength and muscular endurance, awareness or scheme body, pain control and strains. there are few studies evaluating the circular dance effect on back pain. the aim of this study is to compare the effects of lumbar stabilization exercises and circular dance for improvement in non specific low back pain in middle-aged women.

objective: to compare the effect of cd with esl exercises on pain and functional disability in women with nonspecific chronic low back pain (dlci). method: thirty-eight women, aged 35-60 years, were randomly assigned to two groups: 1) circular dance group (gdc); 2) lumbar stabilization exercise group (gesl). the primary clinical outcomes were pain, assessed using the numerical pain scale and functional disability by the roland morris disability questionnaire and the secondary outcomes were: depression assessed by the beck depression inventory; anxiety by the numerical anxiety scale; global perception with the global effect perception scale, signs and symptoms of adverse effects analyzed by the collective subject discourse and quality of life method using the short-form health survey questionnaire (sf-36). the groups were treated twice a week for 60 minutes for 8 weeks totaling 16 sessions. each participant was assessed before and after treatment and at follow-up 12 and 24 weeks.

Eligibility criteria:
inclusion criteria: * diagnose of non specific low back pain for a period of three months without radiculopathy symptoms * seek treatment exclusion criteria: * inflammatory disorders of the spine * spinal tumors * spine surgery * unconsolidated fractures or malunion of the spine * rheumatologic disease * spondylolysis or spondylolisthesis * patients who are in labor dispute * patients undergoing physical therapy or drug treatment to opioid-based

Keywords: low back pain exercise dance therapy physical therapy
sensitivity to change of the lower extremity functional scale in patients with stroke

Conditions: Lower Extremity Dysfunction; Stroke

Summary: the purpose of this study was to investigate the reliability, construct validity, and sensitivity to change of the lower extremity functional scale (lefs) in individuals affected by stroke.

the purpose of this study was to investigate the reliability, construct validity, and sensitivity to change of the lower extremity functional scale (lefs) in individuals affected by stroke. patients were measured with the lefs at the beginning and end of physical therapy treatment, or at 8 weeks of physical therapy treatment.

Eligibility criteria:
inclusion criteria: * medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction due to stroke exclusion criteria: * unable to understand english * more than moderate assist for bed mobility and coming to sitting from the supine position * lower extremity amputation * unable to reach overhead, grasp an object, or feed self with an upper extremity